CRBP stock page - price, fundamentals, dividends - iOCharts

CRBP

1.37
-0.05 (-3.52%)
Corbus Pharmaceuticals Holdings, Inc (NASDAQ, USD)
Healthcare >
Biotechnology
Market cap
171.30M
Ent value
153.31M
Price/Sales
43.51
Price/Book
1.87
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-61.90%
1 year return
-79.82%
3 year return
-34.61%
5 year return
-13.32%
10 year return
-
Last updated: 2021-08-03

STOCK INFORMATION

Stock chart
Loading...
Stock price data
All-time high10.35
1y analyst estimate2.10
Beta1.78
EPS (TTM)-1.13
Dividend per share-
Ex-div date-
Next earnings date12 Aug 2021
Downside potential
Loading...
Downside potential data
CRBPS&P500
Current price drop from All-time high-86.76%-
Highest price drop-90.92%-56.47%
Date of highest drop30 Oct 20209 Mar 2009
Avg drop from high-45.09%-11.52%
Avg time to new high94 days13 days
Max time to new high1102 days1805 days

DIVIDENDS

CRBP does not pay dividends

FINANCIALS

Per share
Loading...
Per share data
Current share count125.03M
EPS (TTM)-1.13
FCF per share (TTM)-1.01
Income statement
Loading...
Income statement data
Revenue (TTM)3.94M
Gross profit (TTM)3.28M
Operating income (TTM)-122.81M
Net income (TTM)-111.27M
EPS (TTM)-1.13
EPS (1y forward)-0.42
Margins
Loading...
Margins data
Gross margin (TTM)83.28%
Operating margin (TTM)-3119.20%
Profit margin (TTM)-2826.08%
Balance Sheet
Loading...

Please create a free account or log in to access this chart

Balance Sheet data
Cash66.61M
Net receivables2.27M
Total current assets130.29M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment8.88M
Total assets140.15M
Accounts payable21.36M
Short/Current long term debt18.61M
Total current liabilities23.61M
Total liabilities48.63M
Shareholder's equity91.52M
Net tangible assets91.52M
Cash flow
Loading...

Please create a free account or log in to access this chart

Cash flow data
Operating cash flow (TTM)-99.69M
Capital expenditures (TTM)588.66K
Free cash flow (TTM)-100.27M
Dividends paid (TTM)0.00
Financial returns
Loading...

Please create a free account or log in to access this chart

Financial returns data
Return on Equity-245.76%
Return on Assets-108.77%
Return on Invested Capital-173.82%
Cash Return on Invested Capital-156.64%
COMPANY DETAILS
CRBP (Corbus Pharmaceuticals Holdings, Inc) company logo
Marketcap
171.30M
Marketcap category
Small-cap
Description
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Employees
76
Investor relations
SEC filings
CEO
Yuval Cohen
Country
USA
City
Norwood
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Loading...